Albumin nanostructures as advanced drug delivery systems

Expert Opinion on Drug Delivery

Volumn 13, Issue 11, 2016, Pages 1609-1623

  Karimi, Mahdi ^a   Bahrami, Sajad ^a,b   Ravari, Soodeh Baghaee ^c   Zangabad, Parham Sahandi ^d   Mirshekari, Hamed ^a   Bozorgomid, Mahnaz ^e   Shahreza, Somayeh ^f   Sori, Masume ^a   Hamblin, Michael R ^g,h,i  

^a IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b Nanomedicine Research Association (NRA)   (Iran)

^c UNIVERSITY OF NORTH CAROLINA AT GREENSBORO   (United States)

^d SHARIF UNIVERSITY OF TECHNOLOGY   (Iran)

^e ISLAMIC AZAD UNIVERSITY   (Iran)

^f UNIVERSITY OF TEHRAN   (Iran)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

^h HARVARD MEDICAL SCHOOL   (United States)

ⁱ HARVARD MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY   (United States)

Author keywords

bovine serum albumin; drug delivery systems; Human serum albumin; nanoparticles; ovalbumin

Indexed keywords

ALBUMIN; ALBUMIN CONJUGATE; APOLIPOPROTEIN; BOVINE SERUM ALBUMIN; CELL RECEPTOR; FOLIC ACID; HUMAN ALBUMIN; MACROGOL; MICROSPHERE; MONOCLONAL ANTIBODY; NANOMATERIAL; NANOPARTICLE; OVALBUMIN; RAT SERUM ALBUMIN; SURFACTANT; UNCLASSIFIED DRUG; ALBUMINOID; DRUG; DRUG CARRIER; LIGAND;

BINDING SITE; CANCER THERAPY; CHEMICAL MODIFICATION; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; EMULSION; HUMAN; IMMUNOGENICITY; MICROBUBBLE; ORGAN SYSTEMS; PROTEIN STRUCTURE; REVIEW; SOLVATION; SYNTHESIS; TARGET CELL; ANIMAL; BOVINE; CHEMISTRY; NANOTECHNOLOGY; RAT;

ALBUMINS; ANIMALS; CATTLE; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; LIGANDS; NANOPARTICLES; NANOSTRUCTURES; NANOTECHNOLOGY; PHARMACEUTICAL PREPARATIONS; RATS;

EID: 84991384253     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1080/17425247.2016.1193149     Document Type: Review

References (132)

1. U.Prabhakar, H.Maeda, R.K.Jain, et al. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res. 2013;73(8):2412–2417.
2. Y.Zhang, H.F.Chan, K.W.Leong Advanced materials and processing for drug delivery:the past and the future. Adv Drug Deliv Rev. 2013;65(1):104–120.
3. M.Karimi, N.Solati, M.Amiri, et al. Carbon nanotubes part I:preparation of a novel and versatile drug-delivery vehicle. Expert Opin Drug Deliv. 2015;12(7):1–17.
4. M.Karimi, H.Mirshekari, M.MoosaviBasri, et al. Bacteriophages and phage-inspired nanocarriers for targeted delivery of therapeutic cargos. Adv Drug Deliv Rev. 2016. doi:10.1016/j.addr.2016.03.003. [Epub ahead of print]
5. J.Nicolas, S.Mura, D.Brambilla, et al. Design, functionalization strategies and biomedical applications of targeted biodegradable/biocompatible polymer-based nanocarriers for drug delivery. Chem Soc Rev. 2013;42(3):1147–1235.
6. M.Karimi, N.Solati, A.Ghasemi, et al. Carbon nanotubes part II:a remarkable carrier for drug and gene delivery. Expert Opin Drug Deliv. 2015;12(7):1–17.
7. P.Couvreur. Nanoparticles in drug delivery:past, present and future. Adv Drug Deliv Rev. 2013;65(1):21–23.
8. M.Karimi, A.Ghasemi, P.S.Zangabad, et al. Smart micro/nanoparticles in stimulus-responsive drug/gene delivery systems. Chem Soc Rev. 2016;45(5):1457–1501.
9. F.Kratz. Albumin as a drug carrier:design of prodrugs, drug conjugates and nanoparticles. J Controlled Release. 2008;132(3):171–183.• Good review about albumin-based drug delivery systems (DDSs) especially those in different stages of regulatory approval.
10. C.Yewale, D.Baradia, I.Vhora, et al. Proteins:emerging carrier for delivery of cancer therapeutics. Expert Opin Drug Deliv. 2013;10(10):1429–1448.
11. T.Peters. Serum albumin. Adv Protein Chem. 1985;37:161–245.
12. J.Han, Q.Wang, Z.Zhang, et al. Cationic bovine serum albumin based self‐assembled nanoparticles as siRNA delivery vector for treating lung metastatic cancer. Small. 2014;10(3):524–535.
13. H.J.Lee, H.H.Park, J.A.Kim, et al. Enzyme delivery using the 30Kc19 protein and human serum albumin nanoparticles. Biomaterials. 2014;35(5):1696–1704.• Discusses silk worm-derived 30Kc19 protein functionalized human serum albumin nanoparticles (HSA NPs) for investigation the 30Kc19 impact on cellular uptake and stability.
14. C.Wolfrum, S.Shi, K.N.Jayaprakash, et al. Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat Biotechnol. 2007;25(10):1149–1157.
15. K.Ren, A.Dusad, R.Dong, et al. Albumin as a delivery carrier for rheumatoid arthritis. J Nanomed Nanotechol. 2013;4(176):2.
16. F.Kratz, B.Elsadek. Clinical impact of serum proteins on drug delivery. J Controlled Release. 2012;161(2):429–445.
17. M.Karimi, P.Avci, R.Mobasseri, et al. The novel albumin–chitosan core–shell nanoparticles for gene delivery:preparation, optimization and cell uptake investigation. J Nanopart Res. 2013;15(5):1–14.
18. H.Kouchakzadeh, S.A.Shojaosadati, F.Shokri. Efficient loading and entrapment of tamoxifen in human serum albumin based nanoparticulate delivery system by a modified desolvation technique. Chem Eng Res Des. 2014;92(9):1681–1692.•• A description of efficient production of HSA nanoparticle-based tamoxifen delivery system.
19. H.E.Misak, R.Asmatulu, J.S.Gopu, et al. Albumin‐based nanocomposite spheres for advanced drug delivery systems. Biotechnol J. 2014;9(1):163–170.
20. I.Steinhauser, B.Spänkuch, K.Strebhardt, et al. Trastuzumab-modified nanoparticles:optimisation of preparation and uptake in cancer cells. Biomaterials. 2006;27(28):4975–4983.
21. H.Kouchakzadeh, M.S.Safavi, S.A.Shojaosadati. Chapter four-efficient delivery of therapeutic agents by using targeted albumin nanoparticles. Adv Protein Chem Struct Biol. 2015;98:121–143.
22. H.Wartlick, K.Michaelis, S.Balthasar, et al. Highly specific HER2-mediated cellular uptake of antibody-modified nanoparticles in tumour cells. J Drug Target. 2004;12(7):461–471.
23. C.Li, D.Zhang, H.Guo, et al. Preparation and characterization of galactosylated bovine serum albumin nanoparticles for liver-targeted delivery of oridonin. Int J Pharm. 2013;448(1):79–86.
24. S.A.Mackowiak, A.Schmidt, V.Weiss, et al. Targeted drug delivery in cancer cells with red-light photoactivated mesoporous silica nanoparticles. Nano Lett. 2013;13(6):2576–2583.
25. G.Zhang, X.Zeng, P.Li. Nanomaterials in cancer-therapy drug delivery system. J Biomed Nanotechnol. 2013;9(5):741–750.
26. M.J.Hawkins, P.Soon-Shiong, N.Desai. Protein nanoparticles as drug carriers in clinical medicine. Adv Drug Deliv Rev. 2008;60(8):876–885.
27. W.J.Gradishar. Albumin-bound paclitaxel:a next-generation taxane. Expert Opin Pharmacother. 2006;7:1041–1053.
28. X.M.He, D.C.Carter. Atomic structure and chemistry of human serum albumin. Nature. 1992;358:209–215.
29. F.Zsila. Subdomain IB is the third major drug binding region of human serum albumin:toward the three-sites model. Mol Pharm. 2013;10(5):1668–1682.•• Introduction of subdomain IB as a new drug-binding region into the HSA protein structure.
30. R.Narazaki, T.Maruyama, M.Otagiri. Probing the cysteine 34 residue in human serum albumin using fluorescence techniques. Biochimica Biophysica Acta (BBA)-Protein Struct Mol Enzymol. 1997;1338(2):275–281.
31. D.C.Carter, X.-M.He, S.H.Munson, et al. Three-dimensional structure of human serum albumin. Science. 1989;244(4909):1195–1198.
32. W.Z-MW, J.X.Ho, J.R.Ruble, et al. Structural studies of several clinically important oncology drugs in complex with human serum albumin. Biochimica Et Biophysica Acta (Bba)-Gensubj. 2013;1830(12):5356–5374.
33. A.O.Elzoghby, W.M.Samy, N.A.Elgindy. Albumin-based nanoparticles as potential controlled release drug delivery systems. J Controlled Release. 2012;157(2):168–182.• Reviews the different types, formulation, and in vitro and in vivo studies concerning albumin DDSs.
34. A.Divsalar, A.A.Saboury, M.Nabiuni, et al. Characterization and side effect analysis of a newly designed nanoemulsion targeting human serum albumin for drug delivery. Colloids Surf B. 2012;98:80–84.
35. Y.-R.Zheng, K.Suntharalingam, T.C.Johnstone, et al. Pt (IV) prodrugs designed to bind non-covalently to human serum albumin for drug delivery. J Am Chem Soc. 2014;136(24):8790–8798.
36. V.T.G.Chuang, M.Otagiri. Stereoselective binding of human serum albumin. Chirality. 2006;18(3):159–166.
37. S.H.Choi, H.J.Byeon, J.S.Choi, et al. Inhalable self-assembled albumin nanoparticles for treating drug-resistant lung cancer. J Controlled Release. 2015;197:199–207.• Uses octyl aldehyde, doxorubicin, and TRAIL protein to form composite HSA NPs that can be inhaled, and studies the anticancer effects.
38. S.Bae, K.Ma, T.H.Kim, et al. Doxorubicin-loaded human serum albumin nanoparticles surface-modified with TNF-related apoptosis-inducing ligand and transferrin for targeting multiple tumor types. Biomaterials. 2012;33(5):1536–1546.
39. F.Dosio, S.Arpicco, P.Brusa, et al. Poly (ethylene glycol)–human serum albumin–paclitaxel conjugates:preparation, characterization and pharmacokinetics. J Controlled Release. 2001;76(1):107–117.
40. S.Wu, X.Huang, X.Du. Glucose‐and pH‐responsive controlled release of cargo from protein‐gated carbohydrate‐functionalized mesoporous silica nanocontainers. Angewandte Chemie. 2013;125(21):5690–5694.
41. L.Zhao, Y.Zhou, Y.Gao, et al. Bovine serum albumin nanoparticles for delivery of tacrolimus to reduce its kidney uptake and functional nephrotoxicity. Int J Pharm. 2015;483(1):180–187.
42. G.Massolini, A.-F.Aubry, A.Mcgann, et al. Determination of the magnitude and enantioselectivity of ligand binding to rat and rabbit serum albumins using immobilized-protein high performance liquid chromatography stationary phases. Biochem Pharmacol. 1993;46(7):1285–1293.
43. J.A.Huntington, P.E.Stein. Structure and properties of ovalbumin. J Chromatogr B Biomed Sci Appl. 2001;756(1):189–198.
44. S.Savadkoohi, A.Bannikova, N.Mantri, et al. Structural properties of condensed ovalbumin systems following application of high pressure. Food Hydrocoll. 2014;53:104–114.
45. F.Niu, Y.Dong, F.Shen, et al. Phase separation behavior and structural analysis of ovalbumin–gum arabic complex coacervation. Food Hydrocoll. 2014;43:1–7.
46. S.Flanary, A.S.Hoffman, P.S.Stayton. Antigen delivery with poly (propylacrylic acid) conjugation enhances MHC-1 presentation and T-cell activation. Bioconjug Chem. 2009;20(2):241–248.
47. D.C.Carter, J.X.Ho. Structure of serum albumin. Adv Protein Chem. 1994;45(45):153–203.
48. N.A.Kratochwil, W.Huber, F.Müller, et al. Predicting plasma protein binding of drugs:a new approach. Biochem Pharmacol. 2002;64(9):1355–1374.
49. T.Kosa, K.Nishi, T.Maruyama, et al. Structural and ligand‐binding properties of serum albumin species interacting with a biomembrane interface. J Pharm Sci. 2007;96(11):3117–3124.
50. C.Dufour, O.Dangles. Flavonoid–serum albumin complexation:determination of binding constants and binding sites by fluorescence spectroscopy. Biochimica Et Biophysica Acta (Bba)-Gensubj. 2005;1721(1):164–173.
51. D.Carter, J.Ho, Z.Wang Albumin binding sites for evaluating drug interactions and methods of evaluating or designing drugs based on their albumin binding properties. Google Patents. 2004.
52. D.C.Carter. Crystallographic survey of albumin drug interaction and preliminary applications in cancer chemotherapy. Burger’s Med Chem Drug Discov. 2010;437–468. doi:10.1002/0471266949.bmc166
53. M.R.Panjehshahin, M.S.Yates, C.J.Bowmer. A comparison of drug binding sites on mammalian albumins. Biochem Pharmacol. 1992;44(5):873–879.
54. L.Morávek, V.Kostka, M.Saber, et al. Peptides isolated from tryptic and chymotryptic digest of fragment CB6 (Pro) of human plasma albumin. Collect Czechoslov Chem Commun. 1975;40(4):1103–1111.
55. U.Anand, S.Mukherjee. Binding, unfolding and refolding dynamics of serum albumins. Biochimica Et Biophysica Acta (Bba)-Gensubj. 2013;1830(12):5394–5404.
56. C.Weber, C.Coester, J.Kreuter, et al. Desolvation process and surface characterisation of protein nanoparticles. Int J Pharm. 2000;194(1):91–102.
57. R.Sadeghi, A.Moosavi-Movahedi, Z.Emam-jomeh, et al. The effect of different desolvating agents on BSA nanoparticle properties and encapsulation of curcumin. J Nanoparticle Res. 2014;16(9):1–14.
58. B.Yedomon, H.Fessi, C.Charcosset. Preparation of Bovine Serum Albumin (BSA) nanoparticles by desolvation using a membrane contactor:A new tool for large scale production. Eur J Pharmaceutics Biopharmaceutics. 2013;85(3):398–405.
59. Q.Y.Li, C.Liu, X.H.Zhao, et al. Preparation, characterization and targeting of micronized 10-hydroxycamptothecin-loaded folate-conjugated human serum albumin nanoparticles to cancer cells. Int J Nanomedicine. 2011;6:397–405.•• Reports a method for cancer cell targeting using folate-conjugated HSA NPs loaded with 10-hydroxycamptothecin.
60. P.Ghosh, A.S.Roy, S.Chaudhury, et al. Preparation of albumin based nanoparticles for delivery of fisetin and evaluation of its cytotoxic activity. Int J Biol Macromol. 2016;86:408–417.
61. X.Wan, X.Zheng, X.Pang, et al. The potential use of lapatinib-loaded human serum albumin nanoparticles in the treatment of triple-negative breast cancer. Int J Pharm. 2015;484(1):16–28.
62. G.Battogtokh, J.H.Kang, Y.T.Ko. Long-circulating self-assembled cholesteryl albumin nanoparticles enhance tumor accumulation of hydrophobic anticancer drug. Eur J Pharmaceutics Biopharmaceutics. 2015;96:96–105.
63. B.Chen, X.-Y.He, X.-Q.Yi, et al. Dual-peptide-functionalized albumin-based nanoparticles with pH-dependent self-assembly behavior for drug delivery. ACS Appl Mater Interfaces. 2015;7(28):15148–15153.
64. M.Martín. nab-Paclitaxel dose and schedule in breast cancer. Breast Cancer Res. 2015;17(1):1–10.
65. K.Husain, S.M.Sebti, M.P.Malafa. Delta-tocotrienol potentiates the antitumor activity of standard chemotherapy with gemcitabine and abraxane in metastatic pancreatic cancer. Cancer Res. 2014;74(19 Supplement):1699–99.
66. P.-L.Lam, S.-L.Kok, R.Gambari, et al. Evaluation of berberine/bovine serum albumin nanoparticles for liver fibrosis therapy. Green Chem. 2015;17(3):1640–1646.
67. I.M.Steinhauser, K.Langer, K.M.Strebhardt, et al. Effect of trastuzumab-modified antisense oligonucleotide-loaded human serum albumin nanoparticles prepared by heat denaturation. Biomaterials. 2008;29(29):4022–4028.
68. N.S.Madhav, S.Kala. Review on microparticulate drug delivery system. Int J PharmTech Res. 2011;3:1242–1254.
69. F.G.Hougeir, L.Kircik. A review of delivery systems in cosmetics. Dermatol Ther. 2012;25(3):234–237.
70. S.G.Gayakwad, N.K.Bejugam, N.Akhavein, et al. Formulation and in vitro characterization of spray-dried antisense oligonucleotide to NF-κ B encapsulated albumin microspheres. J Microencapsul. 2009;26(8):692–700.
71. S.Torrado, J.J.Torrado, R.Cadórniga. Topical application of albumin microspheres containing vitamin A drug release and availability. Int J Pharm. 1992;86(2):147–152.
72. H.-Y.Lee, K.A.Mohammed, E.P.Goldberg, et al. Arginine-conjugated albumin microspheres inhibits proliferation and migration in lung cancer cells. Am J Cancer Res. 2013;3(3):266.
73. E.Stride, M.Edirisinghe. Novel microbubble preparation technologies. Soft Matter. 2008;4(12):2350–2359.
74. S.-P.Dang, R.-X.Wang, Y.Zhang, et al. A novel transfection method for eukaryotic cells using polyethylenimine coated albumin microbubbles. Plasmid. 2011;66(1):19–25.
75. J.L.Chen, A.H.Dhanaliwala, A.J.Dixon, et al. Synthesis of albumin microbubbles using a microfluidic device for real-time imaging and therapeutics. In:Ultrasonics Symposium (IUS), 2013 IEEE International. IEEE. 2013;40(2):400–409.
76. J.R.Lindner. Microbubbles in medical imaging:current applications and future directions. Nat Rev Drug Discov. 2004;3(6):527–533.
77. S.Hernot, A.L.Klibanov. Microbubbles in ultrasound-triggered drug and gene delivery. Adv Drug Deliv Rev. 2008;60(10):1153–1166.
78. C.W.Oettinger, M.J.D’souza. Microencapsulated drug delivery:a new approach to pro-inflammatory cytokine inhibition. J Microencapsul. 2012;29(5):455–462.
79. A.Rollett, T.Reiter, P.Nogueira, et al. Folic acid-functionalized human serum albumin nanocapsules for targeted drug delivery to chronically activated macrophages. Int J Pharm. 2012;427(2):460–466.
80. S.H.Jung, S.K.Kim, S.H.Jung, et al. Increased stability in plasma and enhanced cellular uptake of thermally denatured albumin-coated liposomes. Colloids Surf B. 2010;76(2):434–440.
81. W.Weecharangsan, R.J.Lee. Growth inhibition and chemosensitization of human carcinoma cells by human serum albumin-coated liposomal antisense oligodeoxyribonucleotide against bcl-2. Drug Deliv. 2012;19(6):292–297.
82. G.V.Patil. Biopolymer albumin for diagnosis and in drug delivery. Drug Dev Res. 2003;58(3):219–247.
83. R.Zucchi, R.Danesi. Cardiac toxicity of antineoplastic anthracyclines. Curr Med Chem Anticancer Agents. 2003;3:151–171.
84. E.Pereverzeva, I.Treschalin, D.Bodyagin, et al. Influence of the formulation on the tolerance profile of nanoparticle-bound doxorubicin in healthy rats:focus on cardio- and testicular toxicity. Int J Pharm. 2007;337(1–2):346–356.•• Evaluation of the cardiotoxicity and testicular toxicity of doxorubicin-loaded HSA NPs.
85. H.Kouchakzadeh, S.A.Shojaosadati, A.Maghsoudi, et al. Optimization of PEGylation conditions for BSA nanoparticles using response surface methodology. AAPS PharmSciTech. 2010;11(3):1206–1211.
86. W.Lin, M.C.Garnett, S.S.Davis, et al. Preparation and characterisation of rose Bengal-loaded surface-modified albumin nanoparticles. J Controlled Release. 2001;71(1):117–126.
87. S.F.Zhang, C.Kucharski, M.R.Doschak, et al. Polyethylenimine-PEG coated albumin nanoparticles for BMP-2 delivery. Biomaterials. 2010;31(5):952–963.
88. Y.Lu, P.S.Low. Folate-mediated delivery of macromolecular anticancer therapeutic agents. Adv Drug Deliv Rev. 2012;64:342–352.
89. D.M.Zhao, X.H.Zhao, Y.G.Zu, et al. Preparation, characterization, and in vitro targeted delivery of folate-decorated paclitaxel-loaded bovine serum albumin nanoparticles. Int J Nanomedicine. 2010;5:669–677.
90. Z.Y.Shen, Y.Li, K.Kohama, et al. Improved drug targeting of cancer cells by utilizing actively targetable folic acid-conjugated albumin nanospheres. Pharmacological Res. 2011;63(1):51–58.
91. A.Zensi, D.Begley, C.Pontikis, et al. Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neurones. J Controlled Release. 2009;137(1):78–86.
92. J.Kreuter, T.Hekmatara, S.Dreis, et al. Covalent attachment of apolipoprotein A-I and apolipoprotein B-100 to albumin nanoparticles enables drug transport into the brain. J Controlled Release. 2007;118(1):54–58.• Invokes multiple mechanisms for interactions of NPs with the central nervous system.
93. S.Wagner, A.Zensi, S.L.Wien, et al. Uptake mechanism of ApoE-modified nanoparticles on brain capillary endothelial cells as a blood-brain barrier model. Plos One. 2012;7(3):e32568.
94. K.Michaelis, M.M.Hoffmann, S.Dreis, et al. Covalent linkage of apolipoprotein E to albumin nanoparticles strongly enhances drug transport into the brain. J Pharmacol Exp Ther. 2006;317(3):1246–1253.
95. M.G.Anhorn, S.Wagner, J.Kreuter, et al. Specific targeting of HER2 overexpressing breast cancer cells with doxorubicin-loaded trastuzumab-modified human serum albumin nanoparticles. Bioconjug Chem. 2008;19(12):2321–2331.
96. H.Kouchakzadeh, S.A.Shojaosadati, F.Tahmasebi, et al. Optimization of an anti-HER2 monoclonal antibody targeted delivery system using PEGylated human serum albumin nanoparticles. Int J Pharm. 2013;447(1–2):62–69.
97. K.Löw, M.Wacker, S.Wagner, et al. Targeted human serum albumin nanoparticles for specific uptake in EGFR-expressing colon carcinoma cells. Nanomedicine. 2011;7:454–463.•• Describes the targeted accumulation of albumin NPs in EGFR-expressing cancer cells.
98. S.Wagner, F.Rothweiler, M.G.Anhorn, et al. Enhanced drug targeting by attachment of an anti alpha v integrin antibody to doxorubicin loaded human serum albumin nanoparticles. Biomaterials. 2010;31(8):2388–2398.
99. I.Vhora, S.Patil, P.Bhatt, et al. Chapter one-protein–and peptide–drug conjugates:an emerging drug delivery technology. Adv Protein Chem Struct Biol. 2015;98:1–55.
100. D.Sleep, J.Cameron, L.R.Evans. Albumin as a versatile platform for drug half-life extension. Biochimica Et Biophysica Acta (Bba)-Gensubj. 2013;1830(12):5526–5534.
101. M.Merodio, A.Arnedo, M.J.Renedo, et al. Ganciclovir-loaded albumin nanoparticles:characterization and in vitro release properties. Eur J Pharm Sci. 2001;12(3):251–259.
102. A.Arnedo, J.Irache, M.Merodio, et al. Albumin nanoparticles improved the stability, nuclear accumulation and anticytomegaloviral activity of a phosphodiester oligonucleotide. J Controlled Release. 2004;94(1):217–227.
103. B.Luppi, F.Bigucci, G.Corace, et al. Albumin nanoparticles carrying cyclodextrins for nasal delivery of the anti-Alzheimer drug tacrine. Eur J Pharm Sci. 2011;44(4):559–565.
104. J.Irache, M.Merodio, A.Arnedo, et al. Albumin nanoparticles for the intravitreal delivery of anticytomegaloviral drugs. Mini Rev Med Chem. 2005;5(3):293–305.
105. B.Wilson, T.Ambika, R.D.K.Patel, et al. Nanoparticles based on albumin:preparation, characterization and the use for 5-flurouracil delivery. Int J Biol Macromol. 2012;51(5):874–878.
106. F.-Q.Li, H.Su, J.Wang, et al. Preparation and characterization of sodium ferulate entrapped bovine serum albumin nanoparticles for liver targeting. Int J Pharm. 2008;349(1):274–282.
107. B.Wilson, Y.Lavanya, S.Priyadarshini, et al. Albumin nanoparticles for the delivery of gabapentin:preparation, characterization and pharmacodynamic studies. Int J Pharm. 2014;473(1):73–79.•• Enhanced the concentration of an antiepileptic drug in the brain by delivery with albumin NPs.
108. D.Zhao, X.Zhao, Y.Zu, et al. Preparation, characterization, and in vitro targeted delivery of folate-decorated paclitaxel-loaded bovine serum albumin nanoparticles. Int J Nanomedicine. 2010;5:669.
109. Y.Zu, Y.Zhang, X.Zhao, et al. Optimization of the preparation process of vinblastine sulfate (VBLS)-loaded folateconjugated bovine serum albumin (BSA) nanoparticles for tumor-targeted drug delivery using response surface methodology (RSM). Int J Nanomedicine. 2009;4:321.
110. M.Dadparvar, S.Wagner, S.Wien, et al. HI 6 human serum albumin nanoparticles—development and transport over an in vitro blood–brain barrier model. Toxicol Lett. 2011;206(1):60–66.
111. S.Das, R.Banerjee, J.Bellare. Aspirin loaded albumin nanoparticles by coacervation:implications in drug delivery. Trends Biomater Artif Organs. 2005;18(2):203–212.
112. A.Taheri, R.Dinarvand, F.Atyabi, et al. Trastuzumab decorated methotrexate–human serum albumin conjugated nanoparticles for targeted delivery to HER2 positive tumor cells. Eur J Pharm Sci. 2012;47(2):331–340.
113. Y.Zhang, A.Ho, J.Yue, et al. Structural basis and anticancer properties of ruthenium-based drug complexed with human serum albumin. Eur J Med Chem. 2014;86:449–455.
114. H.-N.Xu, H.-J.Chen, B.-Y.Zheng, et al. Preparation and sonodynamic activities of water-soluble tetra-α-(3-carboxyphenoxyl) zinc (II) phthalocyanine and its bovine serum albumin conjugate. Ultrason Sonochem. 2015;22:125–131.
115. A.Martínez, I.Iglesias, R.Lozano, et al. Synthesis and characterization of thiolated alginate-albumin nanoparticles stabilized by disulfide bonds. Eval Drug Delivery Syst Carbohydr Polym. 2011;83(3):1311–1321.
116. K.Yamasaki, V.T.G.Chuang, T.Maruyama, et al. Albumin–drug interaction and its clinical implication. Biochimica Et Biophysica Acta (Bba)-Gensubj. 2013;1830(12):5435–5443.
117. Z.Yang, W.Gong, Z.Wang, et al. A novel drug-polyethylene glycol liquid compound method to prepare 10-hydroxycamptothecin loaded human serum albumin nanoparticle. Int J Pharm. 2015;490(1–2):412–428.
118. L.Dai, C.-X.Li, K.-F.Liu, et al. Self-assembled serum albumin–poly (l-lactic acid) nanoparticles:a novel nanoparticle platform for drug delivery in cancer. RSC Adv. 2015;5(20):15612–15620.
119. B.Bhushan, P.Dubey, S.U.Kumar, et al. Bionanotherapeutics:niclosamide encapsulated albumin nanoparticles as a novel drug delivery system for cancer therapy. RSC Adv. 2015;5(16):12078–12086.
120. P.Nigam, S.Waghmode, M.Louis, et al. Graphene quantum dots conjugated albumin nanoparticles for targeted drug delivery and imaging of pancreatic cancer. J Mater Chem B. 2014;2(21):3190–3195.• Theranostic application of graphene quantum dot-labeled HSA NPs.
121. A.Woods, A.Patel, D.Spina, et al. In vivo biocompatibility, clearance, and biodistribution of albumin vehicles for pulmonary drug delivery. J Controlled Release. 2015;210:1–9.
122. J.Kufleitner, S.Wagner, F.Worek, et al. Adsorption of obidoxime onto human serum albumin nanoparticles:drug loading, particle size and drug release. J Microencapsul. 2010;27(6):506–513.
123. S.Jana, S.Manna, A.K.Nayak, et al. Carbopol gel containing chitosan-egg albumin nanoparticles for transdermal aceclofenac delivery. Colloids Surf B. 2014;114:36–44.
124. D.Brambilla, B.Le Droumaguet, J.Nicolas, et al. Nanotechnologies for Alzheimer’s disease:diagnosis, therapy, and safety issues. Nanomed Nanotechnol Biol Med. 2011;7(5):521–540.
125. W.A.Banks. Drug delivery to the brain in Alzheimer’s disease:consideration of the blood–brain barrier. Adv Drug Deliv Rev. 2012;64(7):629–639.
126. D.J.Llewellyn, K.M.Langa, R.P.Friedland, et al. Serum albumin concentration and cognitive impairment. Curr Alzheimer Res. 2010;7(1):91.
127. M.Algamal, J.Milojevic, N.Jafari, et al. Mapping the interactions between the Alzheimer’s A β-peptide and human serum albumin beyond domain resolution. Biophys J. 2013;105(7):1700–1709.
128. J.S.Doyle, E.Aspinall, D.Liew, et al. Current and emerging antiviral treatments for hepatitis C infection. Br J Clin Pharmacol. 2013;75(4):931–943.
129. F.Kratz. DOXO-EMCH (INNO-206):the first albumin-binding prodrug of doxorubicin to enter clinical trials. Expert Opin Investig Drugs. 2007;16:855–866.
130. J.H.Han, Y.K.Oh, D.S.Kim, et al. Enhanced hepatocyte uptake and liver targeting of methotrexate using galactosylated albumin as a carrier. Int J Pharm. 1999;188(1):39–47.
131. R.Khandelia, S.Bhandari, U.N.Pan, et al. Gold nanocluster embedded albumin nanoparticles for two‐photon imaging of cancer cells accompanying drug delivery. Small. 2015;11(33):4075–4081.
132. M.Karimi, M.Eslami, P.Sahandi‐Zangabad, et al. pH‐Sensitive stimulus‐responsive nanocarriers for targeted delivery of therapeutic agents. Wiley Interdiscip Rev. 2016. doi:10.1002/wnan.1389. [Epub ahead of print]